Attention Deficit Hyperactivity Disorder (ADHD)
Conditions
Keywords
Attention Deficit Hyperactivity Disorder, Methylphenidate Hydrochloride, CONCERTA
Brief summary
The purpose of this long term post-marketing study is to evaluate the effectiveness and safety of osmotic release oral system methylphenidate hydrochloride (OROS-MPH) in participants with Attention Deficit Hyperactivity Disorder (ADHD).
Detailed description
This is an open-label (all people know the identity of the intervention), prospective (study following participants forward in time), self-controlled, long-term post-marketing study in participants with ADHD. The study consists of 3 periods: screening period, wash-out period/run-in period (3 days), and open-label treatment period (12 weeks) which is divided into 2 periods that is dosage adjustment period and dose-optimization period. The total duration of the study is 12 weeks. During the dosage adjustment period, the dose of methylphenidate hydrochloride was adjusted to the optimal dose within 1-3 weeks starting with initial dosage of 18 milligram per day (mg/d) which can be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance. Participants will receive the optimal dose determined during dose adjustment period for 9 weeks during the dose-optimization period. In the study, 2 types of participants will be enrolled in 2 groups (according to condition): OROS-MPH group (participants with ADHD) and the normal children group (healthy participants). The efficacy will be assessed primarily by Digit Span Test and Inattention /Over activity With Aggression (IOWA) Conners evaluation scale. Participants' safety will be monitored throughout the study.
Interventions
Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
Sponsors
Study design
Eligibility
Inclusion criteria
* ADHD children must sign the consent form in person, and their parents or guardian must endorse, in the consent form, participation of the child in the designated research program * Through personal interaction and assessment questionnaire, examine to determine compliance of DSM-IV ADHD diagnostic criteria * According to the judgment of researchers, the ADHD children should have normal intelligence. Normal intelligence is defined as no obvious evidence of mental retardation in general (specific learning disabilities will not be considered mental retardation in general), formal IQ test to be conducted and 85 marks or above ought to be scored * ADHD children should not have been subjected to psychotropic drug treatment within 6 months. Those ADHD children on whom methylphenidate immediate-release tablets treatment is effective (with maximum daily dosage of 60 mg), may be admitted * Normal children with IQ greater than or equal to 85
Exclusion criteria
* Unable to fully comply with the cognitive function test in the laboratory * Known to be allergic to methylphenidate * Consumption of psychoactive drugs currently or in the past 30 days, including use of monoamine oxidase inhibitors, clonidine, other alpha 2 adrenergic receptor agonists, tricyclic antidepressants, theophylline, bishydroxycoumarin etc * History of alcohol, drugs or substances abuse * Have medical history of type I or II bipolar affective disorder, anxiety disorder, schizophrenia or pervasive developmental disorder
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Digit Span Test Total Score at Week 12 | Baseline and Week 12 | The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention. |
| Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1 | Baseline and Week 1 | IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
| Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2 | Baseline and Week 2 | IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
| Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3 | Baseline and Week 3 | IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
| Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7 | Baseline and Week 7 | IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
| Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12 | Baseline and Week 12 | IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| WCST: Percentage of Correct Responses (Rc%) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better. |
| WCST: First Response (Rf) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better. |
| WCST: Percentage of Conceptual Level Responses (Rf%) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better. |
| WCST: Perseverative Responses (Rp) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better. |
| WCST: Perseverative Error Responses (Rpe) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better. |
| WCST: Percentage of Perseverative Error Responses (Rpe%) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better. |
| WCST: Non-Persistent Error Responses (nRpe) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case). |
| WCST: Failure to Maintain Set (Fm) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case). |
| Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 1, 2, 3, 7 and 12 | Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale |
| Coding Test | Baseline and End of Week 12 | The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants. |
| Academic Achievement | Baseline and End of Week 12 | Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately. |
| Number of Participants With Clinical Global Impression - CGI Scale Score | End of Week 1, 2, 3, 7 and 12 | CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed. |
| Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Baseline and End of Week 12 | IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening. |
| Number of Participants Compliant With Treatment | End of Week 12 | Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator. |
| Change From Baseline in Total Scores of Digit Span Test at Week 12 | Baseline and End of Week 12 | The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention. |
| Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Baseline and End of Week 12 | Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint. |
| Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12 | Week 12 | Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale. |
| WCST: Learning to Learn (L-C) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. Learning to learn indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case). |
| Stroop Color Word Naming Test | Baseline and End of Week 12 | This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint. |
| Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better. |
| WCST: Completed Categories (Cc) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response. |
| WCST: Correct Responses (Rc) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better. |
| WCST: Error Responses (Re) | Baseline and End of Week 12 | WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better. |
Countries
China
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| OROS-MPH Group Participants with attention deficit hyperactivity disorder (ADHD) received osmotic release oral system-methylphenidate (OROS-MPH) tablets orally daily, starting at initial dosage of 18 milligram per day (mg/d) which could be increased to 36 mg/d up to a maximum dosage of 54 mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18 mg due to intolerance. | 128 |
| Normal Group Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children. | 40 |
| Total | 168 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Concomitant medication Interference | 0 | 1 |
| Overall Study | Followup exceeded 4 days to visit window | 19 | 0 |
| Overall Study | Lack of Efficacy | 1 | 0 |
| Overall Study | Other | 4 | 0 |
| Overall Study | Protocol Violation | 1 | 0 |
| Overall Study | Withdrawal by Subject | 5 | 0 |
Baseline characteristics
| Characteristic | OROS-MPH Group | Normal Group | Total |
|---|---|---|---|
| Age, Customized 11 to 12 Years | 25 participants | 14 participants | 39 participants |
| Age, Customized 9 to 10 Years | 55 participants | 16 participants | 71 participants |
| Age, Customized Less than 7 to 8 Years | 48 participants 1.47 | 10 participants 1.72 | 58 participants |
| Sex: Female, Male Female | 20 Participants | 17 Participants | 37 Participants |
| Sex: Female, Male Male | 108 Participants | 23 Participants | 131 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 27 / 149 |
| serious Total, serious adverse events | 0 / 149 |
Outcome results
Change From Baseline in Digit Span Test Total Score at Week 12
The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is 16, and the maximum subscore in the Digits Backward is 14, summed for a total score of 30. A higher score is indicative of better recall and attention.
Time frame: Baseline and Week 12
Population: Full Analysis Set (FAS) population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. FAS for normal group included all participants who received baseline assessment scale evaluation and had at least one endpoint assessment scale evaluation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in Digit Span Test Total Score at Week 12 | Baseline | 11.7 Scores on a scale | Standard Deviation 2.25 |
| OROS-MPH Group | Change From Baseline in Digit Span Test Total Score at Week 12 | Change at Week 12 | 1 Scores on a scale | Standard Deviation 1.5 |
| Normal Group | Change From Baseline in Digit Span Test Total Score at Week 12 | Baseline | 13.7 Scores on a scale | Standard Deviation 2.43 |
| Normal Group | Change From Baseline in Digit Span Test Total Score at Week 12 | Change at Week 12 | 0.5 Scores on a scale | Standard Deviation 1.48 |
Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and Week 1
Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1 | Baseline | 10 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in Inattention/Overactivity With Aggression (IOWA) Conners Behavior Rating Scale - I/O Score at Week 1 | Change at Week 1 | -2.7 Scores on a scale | Standard Deviation 2.18 |
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and Week 12
Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12 | Baseline | 10 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 12 | Change at Week 12 | -6.2 Scores on a scale | Standard Deviation 3.08 |
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and Week 2
Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2 | Baseline | 10 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 2 | Change at Week 2 | -4.1 Scores on a scale | Standard Deviation 2.73 |
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and Week 3
Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3 | Baseline | 10 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 3 | Change at Week 3 | -5 Scores on a scale | Standard Deviation 2.81 |
Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7
IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and Week 7
Population: FAS population for OROS-MPH Group. Here N signifies number of participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7 | Baseline | 10 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in IOWA Conners Behavior Rating Scale - I/O Score at Week 7 | Change at Week 7 | -5.8 Scores on a scale | Standard Deviation 2.91 |
Academic Achievement
Mathematics and language scores will be obtained from their corresponding examinations at school. Scores ranges from 0-100 respectively. Mathematics and language would be summarized separately.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Academic Achievement | Chinese Achievement: Basline (n=128, 40) | 77.35 scores on a scale | Standard Deviation 13.791 |
| OROS-MPH Group | Academic Achievement | Chinese Achievement: End of Week 12(n=111, 40) | 83.94 scores on a scale | Standard Deviation 10.737 |
| OROS-MPH Group | Academic Achievement | Mathematical Achievement (MA):Baseline (n=128, 40) | 78.86 scores on a scale | Standard Deviation 15.407 |
| OROS-MPH Group | Academic Achievement | MA: End of Week 12 (n=111, 40) | 86.05 scores on a scale | Standard Deviation 11.579 |
| Normal Group | Academic Achievement | MA: End of Week 12 (n=111, 40) | 96.13 scores on a scale | Standard Deviation 3.625 |
| Normal Group | Academic Achievement | Chinese Achievement: Basline (n=128, 40) | 94.21 scores on a scale | Standard Deviation 4.301 |
| Normal Group | Academic Achievement | Mathematical Achievement (MA):Baseline (n=128, 40) | 96.23 scores on a scale | Standard Deviation 3.641 |
| Normal Group | Academic Achievement | Chinese Achievement: End of Week 12(n=111, 40) | 94.56 scores on a scale | Standard Deviation 4.396 |
Change From Baseline in Completion Time of Stroop Color-word Test at Week 12
Completion time of stroop color-word test in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test will be scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median time of the naming time in the Stroop color word naming test will be accessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure and n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Baseline (n=86, 30, 1) | 23.61 Seconds | Standard Deviation 12.135 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Baseline (n=86, 30, 1) | 20.538 Seconds | Standard Deviation 15.3567 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Change at End of Week 12 (n=82, 27, 1) | -2.164 Seconds | Standard Deviation 5.2669 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Change at End of Week 12 (n=82, 27, 1) | -4.374 Seconds | Standard Deviation 7.5921 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Baseline (n=86, 30, 1) | 22.229 Seconds | Standard Deviation 18.7304 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Baseline (n=86, 30, 1) | 19.515 Seconds | Standard Deviation 14.6203 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Change at End of Week 12 (n=82, 27, 1) | -3.318 Seconds | Standard Deviation 5.6413 |
| OROS-MPH Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Change at End of Week 12 (n=82, 27, 1) | -2.336 Seconds | Standard Deviation 5.3987 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Change at End of Week 12 (n=82, 27, 1) | -1 Seconds | Standard Deviation 4.308 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Change at End of Week 12 (n=82, 27, 1) | -2.996 Seconds | Standard Deviation 6.6313 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Change at End of Week 12 (n=82, 27, 1) | -3.974 Seconds | Standard Deviation 6.0143 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Baseline (n=86, 30, 1) | 17.29 Seconds | Standard Deviation 11.7025 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Baseline (n=86, 30, 1) | 17.7 Seconds | Standard Deviation 13.654 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Change at End of Week 12 (n=82, 27, 1) | -1.233 Seconds | Standard Deviation 3.9809 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Baseline (n=86, 30, 1) | 22.154 Seconds | Standard Deviation 9.2451 |
| Normal Group | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Baseline (n=86, 30, 1) | 17.473 Seconds | Standard Deviation 14.2673 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Change at End of Week 12 (n=82, 27, 1) | 1 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Baseline (n=86, 30, 1) | 5 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 1: Change at End of Week 12 (n=82, 27, 1) | 0 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Baseline (n=86, 30, 1) | 9 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 2: Change at End of Week 12 (n=82, 27, 1) | 0 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Baseline (n=86, 30, 1) | 7 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 3: Change at End of Week 12 (n=82, 27, 1) | 3 Seconds | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Completion Time of Stroop Color-word Test at Week 12 | Test 4: Baseline (n=86, 30, 1) | 15 Seconds | Standard Deviation 0 |
Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12
IOWA conners behavior rating scale score in different dosage groups will be accessed to evaluate relationship between therapeutic effect and dosage. IOWA Conners Behavior Rating Scale evaluated by parents provides accurate measurement standards for behavioral change and therapeutic response. It includes 2 sub-scales: Inattention/Overactivity (I/O) subscale and Attacks (A), also known as Opposition/Defiant (O/D) sub-scale. IO (primary measurement ) will be assessed using 5-items and all Items will be scored on a 4-point scale (from 0=not at all to 3=very much). Total score range is from 0 to 15. Higher scores indicate worsening.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Baseline | 10 Scores on a scale | Standard Deviation 2.42 |
| OROS-MPH Group | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Change at End of Week 12 | -6.8 Scores on a scale | Standard Deviation 2.82 |
| Normal Group | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Baseline | 10.3 Scores on a scale | Standard Deviation 2.39 |
| Normal Group | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Change at End of Week 12 | -5.8 Scores on a scale | Standard Deviation 3.32 |
| OROS-MPH Group 54 mg | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Baseline | 7 Scores on a scale | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in I/O Score of IOWA Conners Behavior Rating Scale at Week 12 | Change at End of Week 12 | -4 Scores on a scale | Standard Deviation 0 |
Change From Baseline in Total Scores of Digit Span Test at Week 12
The digit span test total score will be accessed in different dosage groups to evaluate the relationship between therapeutic effect and dosage. The digit span test is mainly used to measure the ability of short-term memory and attention. The participant will be given a string of digits and asked to repeat them forward, and then a second string of digits to repeat backward. The score is the number of correct responses, where the digits were repeated correctly. One point will be given for each correctly repeated string of digits. The maximum subscore in the Digits Forward is16, and the maximum subscore in the Digits Backward is 14, for a total score of 30. A higher score was indicative of better recall and attention.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Baseline | 11.7 Scores on a scale | Standard Deviation 2.4 |
| OROS-MPH Group | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Change at End of Week 12 | 1.2 Scores on a scale | Standard Deviation 1.54 |
| Normal Group | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Baseline | 11.3 Scores on a scale | Standard Deviation 1.95 |
| Normal Group | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Change at End of Week 12 | 0.8 Scores on a scale | Standard Deviation 1.56 |
| OROS-MPH Group 54 mg | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Change at End of Week 12 | 0 Scores on a scale | Standard Deviation 0 |
| OROS-MPH Group 54 mg | Change From Baseline in Total Scores of Digit Span Test at Week 12 | Baseline | 15 Scores on a scale | Standard Deviation 0 |
Coding Test
The coding Test is a common test indicator for perceptual speed. The test presents a series of corresponding relationship between graphics and symbols to the participant, and then participants will be required to fill out the appropriate symbol following single symbol in the test part. The test is limited within 150 seconds and evaluated the number of symbols been replaced correctly by the participants.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Coding Test | Baseline (n=128, 40) | 63.4 Number of symbols correctly replaced | Standard Deviation 40.14 |
| OROS-MPH Group | Coding Test | End of Week 12 (n=111, 40) | 73.2 Number of symbols correctly replaced | Standard Deviation 41.41 |
| Normal Group | Coding Test | Baseline (n=128, 40) | 77.4 Number of symbols correctly replaced | Standard Deviation 44.83 |
| Normal Group | Coding Test | End of Week 12 (n=111, 40) | 83.1 Number of symbols correctly replaced | Standard Deviation 44.19 |
Number of Participants Compliant With Treatment
Number of Participants who are Compliant with Treatment will be accessed. Less than 80 percent and more than 120 percent compliance signifies bad compliance, 80 to 120 percent compliance signifies good compliance . The compliance was calculated by the percentage of dose (actual dose multiplied by 100/theoretical dose).The theoretical dose means the dose prescribed by the Investigator.
Time frame: End of Week 12
Population: FAS population for OROS-MPH Group. Here N signifies participants who were evaluable for this outcome measure. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| OROS-MPH Group | Number of Participants Compliant With Treatment | Less than 80 percent | 17 participants |
| OROS-MPH Group | Number of Participants Compliant With Treatment | Between 80 to 120 percent | 110 participants |
| OROS-MPH Group | Number of Participants Compliant With Treatment | More than 120 percent | 0 participants |
Number of Participants With Clinical Global Impression - CGI Scale Score
CGI is an overall rating scale. Clinical Global Impression (Improvement of Diseases) is divided into seven grades: 1=very significant improvement, 24=significant improvement or advanced, 3=improvement or slightly advanced, 4=no change, 5=slight aggravation, 6=significant aggravation, and 7=very significant aggravation or seriously aggravated. Number of participants in each category of grade were assessed.
Time frame: End of Week 1, 2, 3, 7 and 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Aggravated: End of Week 12 | 1 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Aggravated: End of Week 1 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Aggravated: End of Week 3 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Aggravated: End of Week 7 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Seriously Aggravated: End of Week 7 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Advanced: End of Week 7 | 41 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Advanced: End of Week 12 | 46 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Advanced: End of Week 1 | 33 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Advanced: End of Week 2 | 28 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Advanced: End of Week 3 | 33 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Advanced: End of Week 7 | 28 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Advanced: End of Week 12 | 25 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | No Change: End of Week 1 | 15 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | No Change: End of Week 2 | 10 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | No Change: End of Week 3 | 11 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | No Change: End of Week 7 | 7 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | No Change: End of Week 12 | 3 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Aggravated: End of Week 1 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Aggravated: End of Week 2 | 2 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Aggravated: End of Week 3 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Slightly Aggravated: End of Week 7 | 3 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Aggravated: End of Week 2 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Aggravated: End of Week 12 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Seriously Aggravated: End of Week 1 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Seriously Aggravated: End of Week 2 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Seriously Aggravated: End of Week 3 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Seriously Aggravated: End of Week 12 | 0 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Significantly Advanced: End of Week 1 | 20 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Significantly Advanced: End of Week 2 | 28 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Significantly Advanced: End of Week 3 | 29 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Significantly Advanced: End of Week 7 | 35 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Significantly Advanced: End of Week 12 | 36 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Advanced: End of Week 1 | 59 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Advanced: End of Week 2 | 53 Participants |
| OROS-MPH Group | Number of Participants With Clinical Global Impression - CGI Scale Score | Advanced: End of Week 3 | 44 Participants |
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale.
Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale
Time frame: End of Week 1, 2, 3, 7 and 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Data for Normal group was not analyzed for IOWA Conners scale since as per the planned analysis normal participants were only analyzed for the memory effect in cognitive function test.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 1 | 25.98 Percentage of Participants |
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 2 | 51.97 Percentage of Participants |
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 3 | 66.93 Percentage of Participants |
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 7 | 78.74 Percentage of Participants |
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale. | End of Week 12 | 81.10 Percentage of Participants |
Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12
Remission rate in different dosage groups will be accessed to evaluate the relationship between therapeutic effect and dosage. Remission rate is the percentage of participants with total score of IO sub-scale less than or equal to 5 in IOWA Conners measurement scale.
Time frame: Week 12
Population: FAS population for OROS-MPH Group included all participants who received at least one study drug therapy and had at least one efficacy evaluation. Here N signifies participants who were evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| OROS-MPH Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12 | 85.37 Percentage of participants |
| Normal Group | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12 | 74.07 Percentage of participants |
| OROS-MPH Group 54 mg | Percentage of Participants With Total Score of IO Sub-scale Less Than or Equal to 5 in IOWA Conners Measurement Scale at Week 12 | 100.00 Percentage of participants |
Stroop Color Word Naming Test
This is a psychological test to observe the interference in which disparity between the meaning and color affects reading speed. A participant will be given 3 tasks of recognition: reading the printed colored ink (Color Test), reading color words in black ink (Word Test), and interference, reading color words printed in different colored ink (Word-Color Test). The test is scored on the number of correct answers. There are 100 items for each of the three categories and if they made it through the 100 words with time remaining, they would repeat the list. Median naming time in the Stroop color word naming test will be assessed. Stroop color word naming test 1 ,2 ,3 and 4 stand for gradually increased difficulty and each test has a corresponding baseline and endpoint.
Time frame: Baseline and End of Week 12
Population: FAS for OROS-MPH Group included participants who took at least 1 study drug therapy and had at least 1 efficacy evaluation. FAS for normal group included participants who had baseline assessment scale evaluation and had at least 1 endpoint assessment scale evaluation. 'n'=participants who were evaluable at each specific time point for each arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Stroop Color Word Naming Test | Test 1: Baseline (n=128, 40) | 20.561 Seconds | Standard Deviation 17.5433 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 3: Baseline (n=128, 40) | 18.652 Seconds | Standard Deviation 14.5219 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 3: End of Week 12 (n=111, 40) | 16.946 Seconds | Standard Deviation 12.1586 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 2: Baseline (n=128, 40) | 19.32 Seconds | Standard Deviation 14.8072 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 4: Baseline (n=128, 40) | 22.868 Seconds | Standard Deviation 11.3502 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 1: End of Week 12 (n=111, 40) | 18.961 Seconds | Standard Deviation 5.4474 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 4: End of Week 12 (n=111, 40) | 19.388 Seconds | Standard Deviation 9.8989 |
| OROS-MPH Group | Stroop Color Word Naming Test | Test 2: End of Week 12 (n=111, 40) | 18.281 Seconds | Standard Deviation 13.6981 |
| Normal Group | Stroop Color Word Naming Test | Test 4: End of Week 12 (n=111, 40) | 10.488 Seconds | Standard Deviation 4.2176 |
| Normal Group | Stroop Color Word Naming Test | Test 1: Baseline (n=128, 40) | 6.213 Seconds | Standard Deviation 2.3174 |
| Normal Group | Stroop Color Word Naming Test | Test 1: End of Week 12 (n=111, 40) | 5.7 Seconds | Standard Deviation 1.8355 |
| Normal Group | Stroop Color Word Naming Test | Test 2: Baseline (n=128, 40) | 7.15 Seconds | Standard Deviation 2.6341 |
| Normal Group | Stroop Color Word Naming Test | Test 2: End of Week 12 (n=111, 40) | 6.675 Seconds | Standard Deviation 2.2886 |
| Normal Group | Stroop Color Word Naming Test | Test 3: End of Week 12 (n=111, 40) | 6.513 Seconds | Standard Deviation 2.3898 |
| Normal Group | Stroop Color Word Naming Test | Test 4: Baseline (n=128, 40) | 11.763 Seconds | Standard Deviation 4.4202 |
| Normal Group | Stroop Color Word Naming Test | Test 3: Baseline (n=128, 40) | 6.875 Seconds | Standard Deviation 2.6451 |
WCST: Completed Categories (Cc)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. In completed categoriies, number of categories completed out of 6 sorting categories after the test was evaluated. Ranges from 0 to 6. The more the number of categories completed the better is the response.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Completed Categories (Cc) | Baseline (n=128, 40) | 3.2 Nunber of Categories Completed | Standard Deviation 1.56 |
| OROS-MPH Group | WCST: Completed Categories (Cc) | End of Week 12 (n=111, 40) | 4.1 Nunber of Categories Completed | Standard Deviation 1.54 |
| Normal Group | WCST: Completed Categories (Cc) | Baseline (n=128, 40) | 3.3 Nunber of Categories Completed | Standard Deviation 1.68 |
| Normal Group | WCST: Completed Categories (Cc) | End of Week 12 (n=111, 40) | 4 Nunber of Categories Completed | Standard Deviation 1.34 |
WCST: Correct Responses (Rc)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The number of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0-116, the more the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Correct Responses (Rc) | Baseline (n=128, 40) | 72.9 number of correct responses | Standard Deviation 15.65 |
| OROS-MPH Group | WCST: Correct Responses (Rc) | End of Week 12 (n=111, 40) | 80.3 number of correct responses | Standard Deviation 12.25 |
| Normal Group | WCST: Correct Responses (Rc) | Baseline (n=128, 40) | 77.9 number of correct responses | Standard Deviation 12.27 |
| Normal Group | WCST: Correct Responses (Rc) | End of Week 12 (n=111, 40) | 84.7 number of correct responses | Standard Deviation 12.3 |
WCST: Error Responses (Re)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of error responses which did not comply with the response principles was evaluated. Ranges from 0 to 128, the less the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Error Responses (Re) | Baseline (n=128, 40) | 52.3 number of error responses | Standard Deviation 18.59 |
| OROS-MPH Group | WCST: Error Responses (Re) | End of Week 12 (n= 111, 40) | 36.1 number of error responses | Standard Deviation 16.93 |
| Normal Group | WCST: Error Responses (Re) | Baseline (n=128, 40) | 42.9 number of error responses | Standard Deviation 17.77 |
| Normal Group | WCST: Error Responses (Re) | End of Week 12 (n= 111, 40) | 32.3 number of error responses | Standard Deviation 15.11 |
WCST: Failure to Maintain Set (Fm)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. The frequency (number of times) of responses completed with 5 to 9 continuous correct was evaluated. Ranges from 0 to 26 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Failure to Maintain Set (Fm) | Baseline (n=128, 40) | 1.7 number of times | Standard Deviation 1.62 |
| OROS-MPH Group | WCST: Failure to Maintain Set (Fm) | End of Week 12 (n=111, 40) | 2 number of times | Standard Deviation 1.78 |
| Normal Group | WCST: Failure to Maintain Set (Fm) | Baseline (n=128, 40) | 2.3 number of times | Standard Deviation 1.65 |
| Normal Group | WCST: Failure to Maintain Set (Fm) | End of Week 12 (n=111, 40) | 2.5 number of times | Standard Deviation 1.75 |
WCST: First Response (Rf)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of responses needed to complete the first color classification was evaluated. Ranges from 9 to 128, the lesser the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: First Response (Rf) | Baseline (n=128,40) | 22.6 number of first responses | Standard Deviation 22.29 |
| OROS-MPH Group | WCST: First Response (Rf) | End of Week 12 (n=111, 40) | 23.4 number of first responses | Standard Deviation 19 |
| Normal Group | WCST: First Response (Rf) | Baseline (n=128,40) | 25.2 number of first responses | Standard Deviation 24.45 |
| Normal Group | WCST: First Response (Rf) | End of Week 12 (n=111, 40) | 26.5 number of first responses | Standard Deviation 22.77 |
WCST: Learning to Learn (L-C)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. Learning to learn indicator was a measure of decrement in the number of responses needed to achieve each successive category. The raw score ranged from 0 to 100. The high, negative value suggests the participants could not effectively learn the task presented by the WCST. Only calculated in those completed 3 or more categories and not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Learning to Learn (L-C) | Baseline (n=128, 40) | -2.49 number of responses | Standard Deviation 6.451 |
| OROS-MPH Group | WCST: Learning to Learn (L-C) | End of Week 12 (n=111, 40) | -1.87 number of responses | Standard Deviation 3.85 |
| Normal Group | WCST: Learning to Learn (L-C) | Baseline (n=128, 40) | -2.37 number of responses | Standard Deviation 6.31 |
| Normal Group | WCST: Learning to Learn (L-C) | End of Week 12 (n=111, 40) | -1.34 number of responses | Standard Deviation 4.391 |
WCST: Non-Persistent Error Responses (nRpe)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Non perseverative error responses are the errors remaining after subtracting persistent errors from total errors. Ranges from 0 to 128 and was not linear (cannot be considered to be good or bad just judged by the number, analyzed with other factors case by case).
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Non-Persistent Error Responses (nRpe) | Baseline (n=128, 40) | 23.54 number of non-persistent error responses | Standard Deviation 11.606 |
| OROS-MPH Group | WCST: Non-Persistent Error Responses (nRpe) | End of Week 12 (n=111, 40) | 16.75 number of non-persistent error responses | Standard Deviation 9.241 |
| Normal Group | WCST: Non-Persistent Error Responses (nRpe) | Baseline (n=128, 40) | 19.98 number of non-persistent error responses | Standard Deviation 8.94 |
| Normal Group | WCST: Non-Persistent Error Responses (nRpe) | End of Week 12 (n=111, 40) | 15.8 number of non-persistent error responses | Standard Deviation 7.737 |
WCST: Percentage of Conceptual Level Responses (Rf%)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of the responses completed with 3-10 continuous correct during the entire measuring process was evaluated. Ranges from 0 to 100%, the more the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Percentage of Conceptual Level Responses (Rf%) | Baseline (n=128, 40) | 46.36 percentage of conceptual level responses | Standard Deviation 18.589 |
| OROS-MPH Group | WCST: Percentage of Conceptual Level Responses (Rf%) | End of Week 12 (n=111, 40) | 61.07 percentage of conceptual level responses | Standard Deviation 17.244 |
| Normal Group | WCST: Percentage of Conceptual Level Responses (Rf%) | Baseline (n=128, 40) | 54.73 percentage of conceptual level responses | Standard Deviation 18.48 |
| Normal Group | WCST: Percentage of Conceptual Level Responses (Rf%) | End of Week 12 (n=111, 40) | 65 percentage of conceptual level responses | Standard Deviation 16.036 |
WCST: Percentage of Correct Responses (Rc%)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of correct responses which meets all the requirements according to the response principles was evaluated. Ranges from 0 to 100 percent (%), the more the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Percentage of Correct Responses (Rc%) | Baseline (n=128, 40) | 58.678 Percentage of correct responses | Standard Deviation 13.8072 |
| OROS-MPH Group | WCST: Percentage of Correct Responses (Rc%) | End of Week 12 (n=111, 40) | 70.096 Percentage of correct responses | Standard Deviation 11.6311 |
| Normal Group | WCST: Percentage of Correct Responses (Rc%) | Baseline (n=128, 40) | 65.52 Percentage of correct responses | Standard Deviation 12.6227 |
| Normal Group | WCST: Percentage of Correct Responses (Rc%) | End of Week 12 (n=111, 40) | 73.34 Percentage of correct responses | Standard Deviation 10.5072 |
WCST: Percentage of Perseverative Error Responses (Rpe%)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative (pvt) errors; nonperseverative errors; failure to maintain set; learning to learn. Percentage of persistent errors out of total number of responses was evaluated. Ranges from 0 to 100%, the less the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Percentage of Perseverative Error Responses (Rpe%) | Baseline (n=128, 40) | 22.67 Percentage of pvt error responses | Standard Deviation 11.658 |
| OROS-MPH Group | WCST: Percentage of Perseverative Error Responses (Rpe%) | End of Week 12 (n=111, 40) | 16.07 Percentage of pvt error responses | Standard Deviation 9.188 |
| Normal Group | WCST: Percentage of Perseverative Error Responses (Rpe%) | Baseline (n=128, 40) | 18.45 Percentage of pvt error responses | Standard Deviation 8.083 |
| Normal Group | WCST: Percentage of Perseverative Error Responses (Rpe%) | End of Week 12 (n=111, 40) | 13.59 Percentage of pvt error responses | Standard Deviation 7.167 |
WCST: Perseverative Error Responses (Rpe)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Perseverative error responses are the number of responses which applied continuity principle for matching answers and also had the wrong answer was evaluated. Ranges from 0 to 128, the less the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Perseverative Error Responses (Rpe) | Baseline (n=128, 40) | 28.7 number of perseverative error responses | Standard Deviation 15.24 |
| OROS-MPH Group | WCST: Perseverative Error Responses (Rpe) | End of Week 12 (n=111, 40) | 19.4 number of perseverative error responses | Standard Deviation 12.54 |
| Normal Group | WCST: Perseverative Error Responses (Rpe) | Baseline (n=128, 40) | 23 number of perseverative error responses | Standard Deviation 11.03 |
| Normal Group | WCST: Perseverative Error Responses (Rpe) | End of Week 12 (n=111, 40) | 16.4 number of perseverative error responses | Standard Deviation 9.85 |
WCST: Perseverative Responses (Rp)
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. Number of perseverative responses were the responses which applied continuity principle for matching answers was evaluated. Ranges from 0 to 100, the less the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | WCST: Perseverative Responses (Rp) | Baseline (n=128, 40) | 33.7 number of perseverative responses | Standard Deviation 20.47 |
| OROS-MPH Group | WCST: Perseverative Responses (Rp) | End of Week 12 (n=111, 40) | 22 number of perseverative responses | Standard Deviation 16.21 |
| Normal Group | WCST: Perseverative Responses (Rp) | Baseline (n=128, 40) | 26.5 number of perseverative responses | Standard Deviation 14.09 |
| Normal Group | WCST: Perseverative Responses (Rp) | End of Week 12 (n=111, 40) | 18.6 number of perseverative responses | Standard Deviation 12.97 |
Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination
WCST is used to evaluate participants' abilities of abstract generalization, working memory, and distraction-cognitive clinically, which reflects participants' cognitive function objectively and comprehensively. WCST consists of 13 test indicators and all indicators will be analyzed separately. The 13 indicators are as follows: number of trials administered; number of categories completed; response corrects; percent corrects; total number of errors; trials to complete first category; percent conceptual level responses; perseverative responses; perseverative errors; percent perseverative errors; nonperseverative errors; failure to maintain set; learning to learn. During number of trials administered or administered responses, participants were administered 128 cards and asked to sort the cards until all the 6 sorting categories was completed. Response number used to complete all 6 categories ranges from 50 to 128, lesser the better.
Time frame: Baseline and End of Week 12
Population: FAS population for OROS-MPH Group included participants who received at least 1 study drug and had at least one efficacy evaluation. FAS for normal group included all participants who had baseline scale evaluation and had at least one endpoint scale evaluation. n signifies participants who were evaluable at each time point for each specific arm.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| OROS-MPH Group | Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination | Baseline (n=128, 40) | 125.1 Responses | Standard Deviation 8.74 |
| OROS-MPH Group | Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination | End of Week 12 (n=111, 40) | 116.4 Responses | Standard Deviation 17.68 |
| Normal Group | Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination | Baseline (n=128, 40) | 120.8 Responses | Standard Deviation 5.53 |
| Normal Group | Wisconsin Card Sorting Test (WCST): Administered Responses (Ra) of Completed Examination | End of Week 12 (n=111, 40) | 117.1 Responses | Standard Deviation 17.37 |